Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Q3 2025 earnings

Reported November 5, 2025 · After market close

Revenue$26.1MMiss by $578.9K
EPS-$0.01Beat by $0.01
Revenue estimate$26.6M
EPS estimate-$0.02

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$37.1M
EPS estimate$0.14

Financials

Q3 2025

Income statement

See full
Revenue$26.1M+605%
Gross profit$24.8M+1,683%
Operating income$4.1M+115%
Net income-$544.0K+98.4%
EPS (diluted)-$0.01+98.6%

Balance sheet

See full
Cash & equivalents$54.4M+0.7%
Total debt$62.7M+4.7%
Total equity$133.2M+90.9%
Total assets$270.1M+41.0%

Cash flow

See full
CapEx$554.0K—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$533.84M+83.6%
Enterprise value$542.12M+82.7%
P/E15.1×—
P/S6.3×-5.5×

Profitability

See full
Gross margin80.7%+13.5pp
Operating margin-103.9%-43.0pp
Net margin41.9%+22.1pp

Returns & leverage

See full
Return on equity34.8%+19.4pp
Debt / equity0.5×-0.4×
Current ratio8.6×+5.7×

Segments

By product

See full
MIPLYFFA$22.4M+787%
OLPRUVA$100.0K—

By segment

See full
Reportable Segment$26.1M+605%

FAQ

When did Zevra Therapeutics, Inc. report Q3 2025 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q3 2025 earnings on November 5, 2025 after market close.
What were Zevra Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $26.1M and eps of $-0.01 for Q3 2025.
Did Zevra Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $26.6M by $578.9K. EPS beat the consensus estimate of $-0.02 by $0.01.
How did Zevra Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 605.4% from $3.7M a year earlier and eps grew 98.6% from $-0.69.
Where can I find Zevra Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001434647-25-000009) and the 10-Q periodic report (0001434647-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.